John Choi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4867190/publications.pdf

Version: 2024-02-01

623734 713466 1,089 24 14 21 h-index citations g-index papers 24 24 24 1937 times ranked docs citations citing authors all docs

| # | Article | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Mechanisms of immunotherapy resistance: lessons from glioblastoma. Nature Immunology, 2019, 20, 1100-1109. | 14.5 | 421 |
| 2 | Carboxylated branched poly(\hat{l}^2 -amino ester) nanoparticles enable robust cytosolic protein delivery and CRISPR-Cas9 gene editing. Science Advances, 2019, 5, eaay3255. | 10.3 | 127 |
| 3 | ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma. Theranostics, 2020, 10, 5943-5956. | 10.0 | 76 |
| 4 | A Characterization of Dendritic Cells and Their Role in Immunotherapy in Glioblastoma: From Preclinical Studies to Clinical Trials. Cancers, 2019, 11, 537. | 3.7 | 66 |
| 5 | Contrasting impact of corticosteroids on anti-PD-1 immunotherapy efficacy for tumor histologies located within or outside the central nervous system. Oncolmmunology, 2018, 7, e1500108. | 4.6 | 52 |
| 6 | The Use of Ribavirin as an Anticancer Therapeutic: Will It Go Viral?. Molecular Cancer Therapeutics, 2019, 18, 1185-1194. | 4.1 | 49 |
| 7 | A systematic review and meta-analysis of supratotal versus gross total resection for glioblastoma. Journal of Neuro-Oncology, 2020, 148, 419-431. | 2.9 | 48 |
| 8 | Combination immunotherapy strategies for glioblastoma. Journal of Neuro-Oncology, 2021, 151, 375-391. | 2.9 | 38 |
| 9 | Nonviral polymeric nanoparticles for gene therapy in pediatric CNS malignancies. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 23, 102115. | 3.3 | 35 |
| 10 | Overall Survival in Malignant Glioma Is Significantly Prolonged by Neurosurgical Delivery of Etoposide and Temozolomide from a Thermo-Responsive Biodegradable Paste. Clinical Cancer Research, 2019, 25, 5094-5106. | 7.0 | 32 |
| 11 | Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy. Neuro-Oncology Advances, 2020, 2, vdaa011. | 0.7 | 22 |
| 12 | Combination checkpoint therapy with anti-PD-1 and anti-BTLA results in a synergistic therapeutic effect against murine glioblastoma. Oncolmmunology, 2021, 10, 1956142. | 4.6 | 22 |
| 13 | InÂVivo Bioluminescence Tomography Center of Mass-Guided Conformal Irradiation. International Journal of Radiation Oncology Biology Physics, 2020, 106, 612-620. | 0.8 | 17 |
| 14 | CLEC5A expressed on myeloid cells as a M2 biomarker relates to immunosuppression and decreased survival in patients with glioma. Cancer Gene Therapy, 2020, 27, 669-679. | 4.6 | 15 |
| 15 | Ribavirin as a potential therapeutic for atypical teratoid/rhabdoid tumors. Oncotarget, 2018, 9, 8054-8067. | 1.8 | 15 |
| 16 | Absence of Ischemic Injury after Sacrificing the Superior Petrosal Vein during Microvascular Decompression. Operative Neurosurgery, 2020, 18, 316-320. | 0.8 | 12 |
| 17 | Safety considerations for nanoparticle gene delivery in pediatric brain tumors. Nanomedicine, 2020, 15, 1805-1815. | 3.3 | 12 |
| 18 | Synergy between glutamate modulation and anti–programmed cell death protein 1 immunotherapy for glioblastoma. Journal of Neurosurgery, 2022, 136, 379-388. | 1.6 | 11 |

| # | ARTICLE | IF | CITATION |
|----|---|-----|----------|
| 19 | PD-1+ Monocytes Mediate Cerebral Vasospasm Following Subarachnoid Hemorrhage. Neurosurgery, 2021, 88, 855-863. | 1.1 | 11 |
| 20 | Sustained localized delivery of immunotherapy to lymph nodes reverses immunosuppression and increases long-term survival in murine glioblastoma. Oncolmmunology, 2021, 10, 1940673. | 4.6 | 7 |
| 21 | IMMU-18. IMMUNOGENOMIC RESPONDER PHENOTYPE FROM A PHASE I TRIAL OF ANTI-LAG3 OR ANTI-CD137 ALONE AND IN COMBINATION WITH ANTI-PD-1 IN PATIENTS WITH RECURRENT GBM. Neuro-Oncology, 2019, 21, vi122-vi123. | 1.2 | 1 |
| 22 | TMIC-14. PD-L1 EXPRESSION IS NEGATIVELY CORRELATED TO OUTCOMES IN PATIENTS WITH MGMT METHYLATED PROMOTERS IN GBM. Neuro-Oncology, 2019, 21, vi250-vi250. | 1.2 | 0 |
| 23 | SURG-16. SUPRATOTAL VERSUS GROSS TOTAL RESECTION OF GLIOBLASTOMA: A SYSTEMATIC REVIEW. Neuro-Oncology, 2019, 21, vi243-vi243. | 1.2 | O |
| 24 | IMMU-27. SINGLE CELL RNA-SEQUENCING IDENTIFIES NOVEL BONE MARROW DERIVED MYELOID CELLS IN GLIOBLASTOMA ASSOCIATED WITH TUMOR AGGRESSION. Neuro-Oncology, 2020, 22, ii110-ii110. | 1.2 | 0 |